191 related articles for article (PubMed ID: 38155946)
1. Local recurrence and metastatic disease in pheochromocytomas and sympathetic paragangliomas.
Araujo-Castro M; García Sanz I; Mínguez Ojeda C; Hanzu F; Mora M; Vicente A; Blanco Carrera C; de Miguel Novoa P; López García MDC; Lamas C; Manjón-Miguélez L; Del Castillo Tous M; Rodríguez de Vera P; Barahona San Millán R; Recasens M; Tomé Fernández-Ladreda M; Valdés N; Gracia Gimeno P; Robles Lazaro C; Michalopoulou T; Álvarez Escolá C; García Centeno R; Barca-Tierno V; Herrera-Martínez AD; Calatayud M
Front Endocrinol (Lausanne); 2023; 14():1279828. PubMed ID: 38155946
[TBL] [Abstract][Full Text] [Related]
2. Predictors of recurrence of pheochromocytoma and paraganglioma: a multicenter study in Piedmont, Italy.
Parasiliti-Caprino M; Lucatello B; Lopez C; Burrello J; Maletta F; Mistrangelo M; Migliore E; Tassone F; La Grotta A; Pia A; Reimondo G; Giordano R; Giraudo G; Piovesan A; Ciccone G; Deandreis D; Limone P; Orlandi F; Borretta G; Volante M; Mulatero P; Papotti M; Aimaretti G; Terzolo M; Morino M; Pasini B; Veglio F; Ghigo E; Arvat E; Maccario M
Hypertens Res; 2020 Jun; 43(6):500-510. PubMed ID: 31586159
[TBL] [Abstract][Full Text] [Related]
3. LncRNA expression and SDHB mutations in pheochromocytomas and paragangliomas.
Li H; Hardin H; Zaeem M; Huang W; Hu R; Lloyd RV
Ann Diagn Pathol; 2021 Dec; 55():151801. PubMed ID: 34461576
[TBL] [Abstract][Full Text] [Related]
4. Determinants of disease-specific survival in patients with and without metastatic pheochromocytoma and paraganglioma.
Pamporaki C; Prodanov T; Meuter L; Berends AMA; Bechmann N; Constantinescu G; Beuschlein F; Remde H; Januszewicz A; Kerstens MN; Timmers HJLM; Taïeb D; Robledo M; Lenders JWM; Pacak K; Eisenhofer G
Eur J Cancer; 2022 Jul; 169():32-41. PubMed ID: 35500459
[TBL] [Abstract][Full Text] [Related]
5. Chromogranin A in a Cohort of Pheochromocytomas and Paragangliomas: Usefulness at Diagnosis and as an Early Biomarker of Recurrence.
Parisien-La Salle S; Provençal M; Bourdeau I
Endocr Pract; 2021 Apr; 27(4):318-325. PubMed ID: 33581325
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic Deregulation of Protocadherin PCDHGC3 in Pheochromocytomas/Paragangliomas Associated With SDHB Mutations.
Bernardo-Castiñeira C; Valdés N; Celada L; Martinez ASJ; Sáenz-de-Santa-María I; Bayón GF; Fernández AF; Sierra MI; Fraga MF; Astudillo A; Jiménez-Fonseca P; Rial JC; Hevia MÁ; Turienzo E; Bernardo C; Forga L; Tena I; Molina-Garrido MJ; Cacho L; Villabona C; Serrano T; Scola B; Chirivella I; Del Olmo M; Menéndez CL; Navarro E; Tous M; Vallejo A; Athimulam S; Bancos I; Suarez C; Chiara MD
J Clin Endocrinol Metab; 2019 Nov; 104(11):5673-5692. PubMed ID: 31216007
[TBL] [Abstract][Full Text] [Related]
7. Pseudohypoxic pheochromocytomas and paragangliomas dominate in children.
Redlich A; Pamporaki C; Lessel L; Frühwald MC; Vorwerk P; Kuhlen M
Pediatr Blood Cancer; 2021 Jul; 68(7):e28981. PubMed ID: 33682326
[TBL] [Abstract][Full Text] [Related]
8. Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status.
Eisenhofer G; Lenders JW; Siegert G; Bornstein SR; Friberg P; Milosevic D; Mannelli M; Linehan WM; Adams K; Timmers HJ; Pacak K
Eur J Cancer; 2012 Jul; 48(11):1739-49. PubMed ID: 22036874
[TBL] [Abstract][Full Text] [Related]
9. Management and outcome of metastatic pheochromocytomas/paragangliomas: a monocentric experience.
De Filpo G; Cantini G; Rastrelli G; Vannini G; Ercolino T; Luconi M; Mannelli M; Maggi M; Canu L
J Endocrinol Invest; 2022 Jan; 45(1):149-157. PubMed ID: 34227051
[TBL] [Abstract][Full Text] [Related]
10. Metastatic Pheochromocytoma and Paraganglioma: Somatostatin Receptor 2 Expression, Genetics, and Therapeutic Responses.
Fischer A; Kloos S; Maccio U; Friemel J; Remde H; Fassnacht M; Pamporaki C; Eisenhofer G; Timmers HJLM; Robledo M; Fliedner SMJ; Wang K; Maurer J; Reul A; Zitzmann K; Bechmann N; Žygienė G; Richter S; Hantel C; Vetter D; Lehmann K; Mohr H; Pellegata NS; Ullrich M; Pietzsch J; Ziegler CG; Bornstein SR; Kroiss M; Reincke M; Pacak K; Grossman AB; Beuschlein F; Nölting S
J Clin Endocrinol Metab; 2023 Sep; 108(10):2676-2685. PubMed ID: 36946182
[TBL] [Abstract][Full Text] [Related]
11. Clinical differences between small and large pheochromocytomas and paragangliomas.
Zhao L; Li Z; Meng X; Fan H; Zhang Z; Zhang Z; Liu Y; Zhou X; Zhu H
Front Endocrinol (Lausanne); 2023; 14():1087506. PubMed ID: 36967797
[TBL] [Abstract][Full Text] [Related]
12. Disentangling of Malignancy from Benign Pheochromocytomas/Paragangliomas.
Kim KY; Kim JH; Hong AR; Seong MW; Lee KE; Kim SJ; Kim SW; Shin CS; Kim SY
PLoS One; 2016; 11(12):e0168413. PubMed ID: 27992508
[TBL] [Abstract][Full Text] [Related]
13. Differences in intraoperative and surgical outcomes between normotensive pheochromocytomas and sympathetic paragangliomas (PPGLs) and hypertensive PPGLs: results from the PHEO-RISK STUDY.
Araujo-Castro M; García Sanz I; Mínguez Ojeda C; Calatayud M; Hanzu F; Mora M; Vicente A; Blanco Carrera C; De Miguel Novoa P; López García MDC; Manjón-Miguélez L; Rodríguez de Vera P; Del Castillo Tous M; Barahona San Millán R; Recasens M; Tomé Fernández-Ladreda M; Valdés N; Gracia Gimeno P; Robles Lazaro C; Michalopoulou T; Álvarez Escolá C; García Centeno R; Lamas C
J Endocrinol Invest; 2023 Apr; 46(4):805-814. PubMed ID: 36323983
[TBL] [Abstract][Full Text] [Related]
14. Recurrent Disease in Patients With Sporadic Pheochromocytoma and Paraganglioma.
Li M; Prodanov T; Meuter L; Kerstens MN; Bechmann N; Prejbisz A; Remde H; Timmers HJLM; Nölting S; Talvacchio S; Berends AMA; Fliedner S; Robledo M; Lenders JWM; Pacak K; Eisenhofer G; Pamporaki C
J Clin Endocrinol Metab; 2023 Jan; 108(2):397-404. PubMed ID: 36190922
[TBL] [Abstract][Full Text] [Related]
15. Local-Regional Recurrence of Pheochromocytoma/Paraganglioma: Characteristics, Risk Factors and Outcomes.
Cui Y; Ma X; Gao Y; Chang X; Chen S; Lu L; Tong A
Front Endocrinol (Lausanne); 2021; 12():762548. PubMed ID: 34899602
[TBL] [Abstract][Full Text] [Related]
16. Recommendations for somatic and germline genetic testing of single pheochromocytoma and paraganglioma based on findings from a series of 329 patients.
Currás-Freixes M; Inglada-Pérez L; Mancikova V; Montero-Conde C; Letón R; Comino-Méndez I; Apellániz-Ruiz M; Sánchez-Barroso L; Aguirre Sánchez-Covisa M; Alcázar V; Aller J; Álvarez-Escolá C; Andía-Melero VM; Azriel-Mira S; Calatayud-Gutiérrez M; Díaz JÁ; Díez-Hernández A; Lamas-Oliveira C; Marazuela M; Matias-Guiu X; Meoro-Avilés A; Patiño-García A; Pedrinaci S; Riesco-Eizaguirre G; Sábado-Álvarez C; Sáez-Villaverde R; Sainz de Los Terreros A; Sanz Guadarrama Ó; Sastre-Marcos J; Scolá-Yurrita B; Segura-Huerta Á; Serrano-Corredor Mde L; Villar-Vicente MR; Rodríguez-Antona C; Korpershoek E; Cascón A; Robledo M
J Med Genet; 2015 Oct; 52(10):647-56. PubMed ID: 26269449
[TBL] [Abstract][Full Text] [Related]
17. Characteristics of Pediatric vs Adult Pheochromocytomas and Paragangliomas.
Pamporaki C; Hamplova B; Peitzsch M; Prejbisz A; Beuschlein F; Timmers HJLM; Fassnacht M; Klink B; Lodish M; Stratakis CA; Huebner A; Fliedner S; Robledo M; Sinnott RO; Januszewicz A; Pacak K; Eisenhofer G
J Clin Endocrinol Metab; 2017 Apr; 102(4):1122-1132. PubMed ID: 28324046
[TBL] [Abstract][Full Text] [Related]
18. Value of Immunohistochemical Expression of Apelin, Succinate Dehydrogenase B, Chromogranin B, Human Epidermal Growth Factor Receptor-2, Contactin 4, and Succinyl-CoA Synthetase Subunit Beta in Differentiating Metastatic From Non-Metastatic Pheochromocytoma and Paraganglioma.
Wang Y; Chen D; Pang Y; Xu X; Guan X; Liu L
Front Endocrinol (Lausanne); 2022; 13():882906. PubMed ID: 35574028
[TBL] [Abstract][Full Text] [Related]
19. MANAGEMENT OF ENDOCRINE DISEASE: Recurrence or new tumors after complete resection of pheochromocytomas and paragangliomas: a systematic review and meta-analysis.
Amar L; Lussey-Lepoutre C; Lenders JW; Djadi-Prat J; Plouin PF; Steichen O
Eur J Endocrinol; 2016 Oct; 175(4):R135-45. PubMed ID: 27080352
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-210 May Be a Preoperative Biomarker of Malignant Pheochromocytomas and Paragangliomas.
Ruff SM; Ayabe RI; Malekzadeh P; Good ML; Wach MM; Gonzales MK; Tirosh A; Nilubol N; Pacak K; Kebebew E; Patel D
J Surg Res; 2019 Nov; 243():1-7. PubMed ID: 31146085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
